NCT06576037 2026-04-16
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Phase 1 Recruiting
M.D. Anderson Cancer Center
Byondis B.V.
Genmab
University of Chicago
Eucure (Beijing) Biopharma Co., Ltd
Athenex, Inc.
Ipsen
Harbour BioMed (Guangzhou) Co. Ltd.
Merck Sharp & Dohme LLC
University of Virginia